Subtopic Deep Dive
Autoimmune Hemolytic Anemia Blood Groups
Research Guide
What is Autoimmune Hemolytic Anemia Blood Groups?
Autoimmune Hemolytic Anemia Blood Groups studies the role of blood group antigens in autoantibody specificity, direct antiglobulin test (DAT) patterns, and transfusion challenges in warm and cold AIHA.
AIHA involves autoantibodies targeting red blood cell antigens, often linked to blood group systems, complicating transfusion compatibility. Research covers serological patterns in drug-induced and secondary AIHA, with over 1400 citations across key papers. Complement activation and ABO incompatibility in transplants are central mechanisms (Hill et al., 2017; Barcellini et al., 2020).
Why It Matters
Blood group phenotyping in AIHA guides transfusion selection for refractory cases, reducing hemolytic reactions (Petz, 2003, 70 citations). In HSCT patients, minor ABO-incompatible transfusions cause hemolysis without methotrexate, informing protocols (Gajewski et al., 1992, 87 citations). Daratumumab treats post-HSCT AIHA, improving survival (Schuetz et al., 2018, 108 citations). Guidelines standardize management of secondary AIHA tied to lymphoproliferative disorders (Hill et al., 2017, 143 citations).
Key Research Challenges
Transfusion Compatibility in AIHA
Selecting 'least incompatible' units risks hemolysis due to autoantibody interference with crossmatching (Petz, 2003). Serological complexity arises from warm autoantibodies masking blood group antigens. Garratty (2008, 81 citations) questions full understanding of immune RBC destruction mechanisms.
ABO Incompatibility Post-HSCT
Group O RBCs hemolyze in minor ABO-incompatible BMT without posttransplant methotrexate (Gajewski et al., 1992, 87 citations). Donor-derived isohemagglutinins destroy recipient cells despite cyclosporine. Gajewski et al. (2008, 97 citations) review transfusion practices in HPC transplantation.
Complement in Hemolytic Reactions
Complement activation drives transfusion-related hemolysis, varying by antibody class (Stowell et al., 2012, 73 citations). Biomarkers like C3d help interpret DAT in AIHA (Nilsson Ekdahl et al., 2018, 111 citations). Regulation failures exacerbate reactions in autoimmune settings.
Essential Papers
Guidelines on the management of drug‐induced immune and secondary autoimmune, haemolytic anaemia
Quentin A. Hill, R. Stamps, Edwin Massey et al. · 2017 · British Journal of Haematology · 143 citations
The objective of this guideline is to provide healthcare professionals with guidance on the management of patients with secondary autoimmune haemolytic anaemia (AIHA). The guidance may not be appro...
New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy
Wilma Barcellini, Anna Zaninoni, Juri Alessandro Giannotta et al. · 2020 · Journal of Clinical Medicine · 111 citations
Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogen...
Interpretation of Serological Complement Biomarkers in Disease
Kristina Nilsson Ekdahl, Barbro Persson, Camilla Mohlin et al. · 2018 · Frontiers in Immunology · 111 citations
Complement system aberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions in...
Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation
Catharina Schuetz, Manfred Hoenig, Despina Moshous et al. · 2018 · Blood Advances · 108 citations
Abstract New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post–hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immu...
A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation
James Gajewski, Viviana V. Johnson, S. Gerald Sandler et al. · 2008 · Blood · 97 citations
Abstract The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are pe...
Hemolysis of transfused group O red blood cells in minor ABO- incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate
JL Gajewski, L. D. Petz, Loni Calhoun et al. · 1992 · Blood · 87 citations
Hemolysis most commonly occurs following bone marrow transplant when there is “minor” ABO blood group incompatibility between donor and recipient. The hemolysis has been attributed to destruction o...
The James Blundell Award Lecture 2007: Do we really understand immune red cell destruction?
George Garratty · 2008 · Transfusion Medicine · 81 citations
summary We have learned a great deal about immune red blood cell (RBC) destruction since the elaboration of biochemical/immunological interactions of antibodies, complement and macrophages during t...
Reading Guide
Foundational Papers
Start with Gajewski et al. (1992, 87 citations) for ABO hemolysis mechanisms and Petz (2003, 70 citations) critiquing 'least incompatible' transfusions, as they establish core serological challenges.
Recent Advances
Study Barcellini et al. (2020, 111 citations) for pathogenesis updates and Schuetz et al. (2018, 108 citations) for daratumumab in post-HSCT AIHA.
Core Methods
Core techniques: DAT for autoantibody detection (Garratty, 2008), complement assays (Stowell et al., 2012; Nilsson Ekdahl et al., 2018), and crossmatch protocols in incompatibility (Gajewski et al., 2008).
How PapersFlow Helps You Research Autoimmune Hemolytic Anemia Blood Groups
Discover & Search
Research Agent uses searchPapers on 'AIHA blood group transfusion' to find Hill et al. (2017, 143 citations), then citationGraph reveals downstream guidelines and exaSearch uncovers Barcellini et al. (2020) on pathogenesis.
Analyze & Verify
Analysis Agent applies readPaperContent to Schuetz et al. (2018) for daratumumab protocols, verifyResponse with CoVe cross-checks claims against Gajewski et al. (1992), and runPythonAnalysis computes hemolysis rates from datasets with statistical verification; GRADE grades evidence as high for HSCT guidelines.
Synthesize & Write
Synthesis Agent detects gaps in ABO-incompatibility treatments via contradiction flagging across Petz (2003) and Stowell (2012); Writing Agent uses latexEditText for protocols, latexSyncCitations for 10+ papers, latexCompile for figures, and exportMermaid diagrams DAT patterns.
Use Cases
"Analyze hemolysis incidence in minor ABO-incompatible HSCT from Gajewski 1992"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas on incidence data) → statistical output with p-values and GRADE B evidence.
"Draft LaTeX review on AIHA transfusion guidelines citing Hill 2017"
Synthesis Agent → gap detection → Writing Agent → latexEditText → latexSyncCitations (Hill et al., Barcellini et al.) → latexCompile → PDF with bibliography.
"Find code for simulating complement activation in hemolytic reactions"
Research Agent → citationGraph (Stowell 2012) → Code Discovery: paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for Stowell model.
Automated Workflows
Deep Research workflow scans 50+ AIHA papers via searchPapers → citationGraph, generating structured reports on blood group correlations with GRADE scoring. DeepScan applies 7-step analysis with CoVe checkpoints to verify transfusion protocols from Gajewski et al. (2008). Theorizer builds hypotheses on daratumumab efficacy from Schuetz et al. (2018) and Barcellini et al. (2020).
Frequently Asked Questions
What defines Autoimmune Hemolytic Anemia Blood Groups?
AIHA Blood Groups examines blood group antigen targeting by autoantibodies in warm/cold types, DAT patterns, and transfusion issues (Barcellini et al., 2020).
What are key methods in AIHA transfusion research?
Methods include DAT interpretation, 'least incompatible' unit selection, and complement biomarker analysis (Petz, 2003; Nilsson Ekdahl et al., 2018).
What are seminal papers?
Hill et al. (2017, 143 citations) on secondary AIHA guidelines; Gajewski et al. (1992, 87 citations) on ABO hemolysis; Garratty (2008, 81 citations) on RBC destruction.
What open problems exist?
Challenges persist in predicting hemolysis post-HSCT without methotrexate and standardizing daratumumab use in refractory AIHA (Schuetz et al., 2018; Gajewski et al., 1992).
Research Blood groups and transfusion with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Autoimmune Hemolytic Anemia Blood Groups with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Blood groups and transfusion Research Guide